Questionable perks bestowed on top corporate executives could be the next scandal to shake America's boardrooms, as the number of companies involved in a widening federal investigation into the timing of stock option grants grew on Monday.
More than a dozen companies -- from high-flying technology names to a pharmacy benefits manager -- have received inquiries from the U.S. Attorney in New York and the Securities and Exchange Commission seeking details on how they grant stock options to executives.
The companies are being targeted for juicing up the payoff of stock options by backdating their grants to coincide with a point where the stock prices had dropped to lows.
The practice, if proven, meant executives were able to reap profit as their companies' stocks rose well above the options exercise price.
Not only have some corporate officers ensnared in the investigation lost their jobs, but a former SEC head and other corporate governance experts project the inquiry could create a firestorm on Wall Street.
UnitedHealth Group Inc. is so far the biggest company to be enveloped in the investigation, saying in a statement last week it was subpoenaed by the Department of Justice.
Most of the others that have acknowledged being targeted were technology companies, including networker Juniper Networks Inc. and semiconductor-equipment maker KLA-Tencor Corp.
The fact that there are at least 20 companies already involved "indicates more of this went on than anyone could have imagined," said former SEC Chairman Harvey Pitt, whose tenure saw the collapse of Enron Corp., and a major accounting scandal rattle the Big Four firms.
The SEC -- currently headed by Christopher Cox -- is poised to make the biggest changes in rules governing disclosure of executive compensation since 1992. Under rules now being finalized, companies could be required starting next year to detail in annual filings the total yearly compensation for the chairman and the next four highest-paid execs.
